Abstract: The invention relates to a method for therapy guidance, stratification and/or control in a patient with symptoms of an infectious disease, comprising a prognosis of disease progression, the method comprising: providing a sample from said patient, and determining a level of proADM or fragment(s) thereof in said sample, wherein a low risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is not at risk of a disease progression to a condition that requires hospitalization, wherein said low risk level is preferably equal or below 1.2 nmol/l±20%, and/or wherein a high risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is at risk of a disease progression to a condition that requires hospitalization, wherein said high risk level is preferably above 1.2 nmol/l±20%. The invention further relates to a test kit for carrying out the method.
Type:
Application
Filed:
August 8, 2019
Publication date:
September 23, 2021
Applicants:
B.R.A.H.M.S GmbH, Instituto de Investigación Biomédica de Salamanca
Inventors:
Darius Wilson, Jesús Francisco Bermejo Martin, Luis Garcia Ortiz, Carmen Herrero Rodriguez
Abstract: An antibody or fragment thereof, against presenilin, and more specifically against the luminal loop 1 of presenilin, far use in the prevention and/or treatment of cancer, by way of administrating a therapeutically effective quantity of the antibody or a fragment thereof, or a pharmaceutical composition comprising thereof, to a subject who suffers from cancer.
Type:
Application
Filed:
August 3, 2018
Publication date:
November 12, 2020
Applicants:
ALZHEIMUR 2012 S.L., FUNDACIÓN UNIVERSITARIA SAN ANTONIO, IBSAL (INSTITUTO DE INVESTIGACIÓN BIOMEDICA DE SALAMANCA), UNIVERSIDAD DE SALAMANCA
Inventors:
Rogelio GONZALEZ SARMIENTO, Miguel RODRIGUEZ MANOTAS, Javier FERNANDEZ MATEOS, Juan Carlos GALLAR RUIZ, David FLORENCIANO GOMEZ